Patients with high HIV risk are aware of preventative pill, but few are using it Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers. The study, published in the journal AIDS and Behavior, surveyed 202 young sexual minority men and transgender women - two high-priority populations for HIV prevention - to better understand why some were more likely than others to be taking PrEP. According to the Centers for Disease Control and Prevention, sexual minority men are the community most impacted by HIV, making up 69 percent of all new diagnoses in 2018, and transgender populations are disproportionately affected by HIV and prevention challenges. While Black and Hispanic/Latinx populations are mostly likely to be newly diagnosed with HIV, PrEP users are more likely to be white.